US 7410979
Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
granted A61KA61K31/16A61K31/42
Quick answer
US patent 7410979 (Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 07 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Aug 12 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 07 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/16, A61K31/42, A61K31/4439, A61K31/7056